Third Harmonic Bio, Inc. (THRD)
(Delayed Data from NSDQ)
$12.89 USD
+1.10 (9.33%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THRD 12.89 +1.10(9.33%)
Will THRD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for THRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THRD
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
THRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Other News for THRD
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q2 2024
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio GAAP EPS of $0.46
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update